MANDYS1(3B7)

(0) No Reviews yet
$40.00
SKU: MANDYS1(3B7)
View product citations for antibody MANDYS1(3B7) on CiteAb

In Stock

Available: 69

DSHB Data Sheet

Catalog Fields

Antigen: Dystrophin, exons 31/32
Hybridoma Cells Available: Yes
Antigen Species: human
Depositor: Morris, G.E.
Isotype: MIgG2a
Antigen Sequence:
Host Species: mouse
Depositors Institution: Wolfson Centre for Inherited Neuromuscular Disease, RJAH Orthopaedic Hospital, Oswestry, UK
Positive Tested Species Reactivity: Canine, Human, Mouse, Pig, Rabbit
Depositors Notes: This antibody does not work with Xenopus
Antigen Molecular Weight: Predicted: 427 kDa; Apparent: 427 kDa
Human Protein Atlas:  
Predicted Species Reactivity:  
Gene: DMD
Immunogen: Recombinant LacZ/dystrophin (aa 816-1749, rod domain of isoform 4 (Uniprot ID P11532-1)) fusion protein
Alternate Gene Names: BMD, CMD3B, MRX85
Alternate Antibody Name:
Clonality: Monoclonal
Alternate Antigen Name:
Epitope Mapped: Yes
Myeloma Strain: NS0 or Sp2/0
Epitope Location or Sequence: exons 31/32, aa 1431-1505 (repeats 10 and 11 of the central rod domain)
Uniprot ID: P11532 
Immunogen Sequence: Partial protein
Entrez Gene ID: 1756 
Antibody Registry ID: AB_528206 
Additional Information:
Recommended Applications: ELISA, Immunofluorescence, Immunoprecipitation, Western Blot
These hybridomas were created by your colleagues. Please acknowledge the hybridoma contributor and the Developmental Studies Hybridoma Bank (DSHB) in the Materials and Methods of your publications. Please email the citation to us.
For your Materials & Methods section:
MANDYS1(3B7) was deposited to the DSHB by Morris, G.E. (DSHB Hybridoma Product MANDYS1(3B7))
Storage and Handling Recommendations
Although many cell products are maintained at 4°C for years without loss of activity, shelf-life at 4°C is highly variable. For immediate use, short term storage at 4°C up to two weeks is recommended. For long term storage, divide the solution into volumes of no less than 20 ul for freezing at -20°C or -80°C. The small volume aliquot should provide sufficient reagent for short term use. Freeze-thaw cycles should be avoided. For concentrate or bioreactor products, an equal volume of glycerol, a cryoprotectant, may be added prior to freezing.
Usage Recommendations
Although the optimal Ig concentration for an application varies for each product and must be optimized for each laboratory, a good starting concentration for immunohistochemistry (IHC), immunofluorescence (IF), and immunocytochemistry (ICC) is 2-5 ug/ml. For western blots, the recommended concentration range is 0.2-0.5 ug/ml.
All cell products contain the antimicrobial ProClin. Click here for additional information.

14 References

  • Initial Publication
  • IF References
  • WB References
  • IP References
  • ELISA References
  • Epitope Map References
  • All References
  • Initial Publication
    IF References

    Monoclonal antibodies against defined regions of the muscular dystrophy protein, dystrophin.
    Davies KE
    FEBS letters 262.2 (1990 Mar 26): 237-40.

    Improvement of maternal vitamin D status with 25-hydroxycholecalciferol positively impacts porcine fetal skeletal muscle development and myoblast activity.
    Starkey JD
    Journal of animal science 91.9 (2013 Sep): 4116-22.

    Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy.
    Morris GE
    American journal of human genetics 52.6 (1993 Jun): 1057-66.

    Monoclonal antibodies for clinical trials of Duchenne muscular dystrophy therapy.
    Morris GE
    Neuromuscular disorders : NMD 24.3 (2014 Mar): 195-200.

    Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of duchenne muscular dystrophy by immunostaining and western blot.
    Duan D
    PloS one 9.2 (2014): e88280.

    Monitoring duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies.
    Sewry CA
    Methods in molecular biology (Clifton, N.J.) 709. (2011): 39-61.

    Myoblast transfer in the treatment of Duchenne's muscular dystrophy.
    Rice R
    The New England journal of medicine 333.13 (1995 Sep 28): 832-8.

    Myocardial dystrophin immunolocalization at sarcolemma and transverse tubules.
    Schaper J
    Experientia 48.6 (1992 Jun 15): 614-6.

    Co-localization and molecular association of dystrophin with laminin at the surface of mouse and human myotubes.
    Walsh FS
    Journal of cell science 103 ( Pt 4). (1992 Dec): 1223-33.

    WB References
    IP References

    Monitoring duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies.
    Sewry CA
    Methods in molecular biology (Clifton, N.J.) 709. (2011): 39-61.

    Co-localization and molecular association of dystrophin with laminin at the surface of mouse and human myotubes.
    Walsh FS
    Journal of cell science 103 ( Pt 4). (1992 Dec): 1223-33.

    A 71-kilodalton protein is a major product of the Duchenne muscular dystrophy gene in brain and other nonmuscle tissues.
    Nudel U
    Proceedings of the National Academy of Sciences of the United States of America 89.12 (1992 Jun 15): 5346-50.

    Does the survival motor neuron protein (SMN) interact with Bcl-2?
    Burghes AH
    Journal of medical genetics 37.7 (2000 Jul): 536-9.

    ELISA References
    Epitope Map References
    All References

    Monoclonal antibodies against defined regions of the muscular dystrophy protein, dystrophin.
    Davies KE
    FEBS letters 262.2 (1990 Mar 26): 237-40.

    Improvement of maternal vitamin D status with 25-hydroxycholecalciferol positively impacts porcine fetal skeletal muscle development and myoblast activity.
    Starkey JD
    Journal of animal science 91.9 (2013 Sep): 4116-22.

    Use of epitope libraries to identify exon-specific monoclonal antibodies for characterization of altered dystrophins in muscular dystrophy.
    Morris GE
    American journal of human genetics 52.6 (1993 Jun): 1057-66.

    Monoclonal antibodies for clinical trials of Duchenne muscular dystrophy therapy.
    Morris GE
    Neuromuscular disorders : NMD 24.3 (2014 Mar): 195-200.

    Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of duchenne muscular dystrophy by immunostaining and western blot.
    Duan D
    PloS one 9.2 (2014): e88280.

    Monitoring duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies.
    Sewry CA
    Methods in molecular biology (Clifton, N.J.) 709. (2011): 39-61.

    Myoblast transfer in the treatment of Duchenne's muscular dystrophy.
    Rice R
    The New England journal of medicine 333.13 (1995 Sep 28): 832-8.

    Myocardial dystrophin immunolocalization at sarcolemma and transverse tubules.
    Schaper J
    Experientia 48.6 (1992 Jun 15): 614-6.

    Co-localization and molecular association of dystrophin with laminin at the surface of mouse and human myotubes.
    Walsh FS
    Journal of cell science 103 ( Pt 4). (1992 Dec): 1223-33.

    Rapid mapping by transposon mutagenesis of epitopes on the muscular dystrophy protein, dystrophin.
    Morris GE
    Nucleic acids research 19.21 (1991 Nov 11): 5889-94.

    A 71-kilodalton protein is a major product of the Duchenne muscular dystrophy gene in brain and other nonmuscle tissues.
    Nudel U
    Proceedings of the National Academy of Sciences of the United States of America 89.12 (1992 Jun 15): 5346-50.

    Does the survival motor neuron protein (SMN) interact with Bcl-2?
    Burghes AH
    Journal of medical genetics 37.7 (2000 Jul): 536-9.

    Monoclonal antibodies for dystrophin analysis. Epitope mapping and improved binding to SDS-treated muscle sections.
    Morris GE
    The Biochemical journal 288 ( Pt 2). (1992 Dec 1): 663-8.

    The N-terminal half of dystrophin is protected from proteolysis in situ.
    Morris GE
    Biochemical and biophysical research communications 209.3 (1995 Apr 26): 1062-7.

    Ratings & Reviews

    No reviews available

    Be the first to Write a Review